4Basebio

4Basebio ROE

The Return on Equity (ROE) of 4Basebio (4BB.L) as of Nov 3, 2026 is -167.19 %. In the previous year, Return on Equity (ROE) was -46.75 % — a change of 257.62% (lower).

ROE

-167.19 %

YoY

257.62%

Last updated:

In 2025, 4Basebio's return on equity (ROE) was -167.19 %, a 257.62% increase from the -46.75 % ROE in the previous year.

The 4Basebio ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
22.38 GBP
Jan 1, 2020
-4.65 GBP
Jan 1, 2021
-27.66 GBP
Jan 1, 2022
-72.33 GBP
Jan 1, 2023
1,557.93 GBP
Jan 1, 2024
-46.75 GBP
Jan 1, 2025
-167.19 GBP
The 4Basebio ROE history
YEARROEYoY
-167.19 %+257.62%
-46.75 %-103.00%
1,557.93 %-2,253.87%
-72.33 %+161.49%
-27.66 %+494.70%
-4.65 %-120.78%
22.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

4Basebio Stock analysis

What does 4Basebio do? 4basebio Plc develops advanced therapy medicinal products using synthetic DNA and non-viral delivery platforms for cell and gene therapies, DNA vaccines, and mRNA solutions. The company manufactures application-specific synthetic DNA for research, therapeutic, and pharmacological use, while also creating non-viral vectors for efficient payload delivery. Its technology enables the production of synthetic DNA constructs, mRNA, and vectors for cell and tissue-specific delivery, targeting applications such as AAV and Lentivirus viral vectors, mRNA vaccines, genome editing, and DNA vaccines. The company focuses on exploiting intellectual property in cell and gene therapies and DNA vaccines to drive innovation and commercialization. The primary customers for 4basebio Plc's products include research institutions, biotechnology firms, and pharmaceutical companies seeking advanced therapeutic solutions. These entities purchase synthetic DNA constructs, non-viral delivery vectors, and specialized DNA-based products for use in developing cell and gene therapies, DNA vaccines, and mRNA therapeutics. The company's offerings are tailored to support the development of safe and effective treatments across multiple therapeutic areas. 4basebio Plc's revenue streams are derived from the manufacturing and supply of synthetic DNA products, non-viral delivery platforms, and intellectual property licensing. The company generates income through the sale of application-specific synthetic DNA for research and therapeutic applications, as well as the development of delivery vectors for targeted therapies. By leveraging its proprietary technology in DNA synthesis and payload delivery, 4basebio Plc positions itself as a key provider of essential components for next-generation biologics and vaccines. 4Basebio is one of the most popular companies on Eulerpool.

ROE Details

Decoding 4Basebio's Return on Equity (ROE)

4Basebio's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing 4Basebio's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

4Basebio's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in 4Basebio’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about 4Basebio stock

Return on Equity (ROE) of 4Basebio is -167.19 % in 2025.

Return on Equity (ROE) of 4Basebio changed from -46.75 % to -167.19 %, representing a 257.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) 4Basebio since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s 4Basebio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — 4Basebio

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — 4Basebio